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Background: Hemodialysis (HD) patients have multiple causes of immune dysfunction and poor immune response
to influenza vaccination. We investigated the antibody response rate to a pandemic H1N1/2009 influenza
vaccination and clinical parameters influencing the induction of antibody responses in HD patients.
Methods: A total of 114 HD patients were vaccinated with a monovalent adjuvanted H1N1 inactivated influenza
vaccine. Titers of neutralizing antibodies were evaluated by hemagglutination inhibition (HI) assay at pre- and
4 weeks after vaccination. Seroconversion was defined as either a pre-vaccination HI titer < 1:10 and a post
vaccination HI titer > 1:40 or a pre-vaccination HI titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI
antibody titer. Seventeen out of 114 HD patients (14.9%) tested positive for antibodies against influenza A/H1N1/
2009 before vaccination. The remaining 97 baseline sero-negative patients were included in the analysis.
Results: Only 30 (30.9%) HD patients had seroconversion 4 weeks after vaccination. The elderly patients, those over
65 years of age, showed significantly lower seroconversion rate compared to younger HD patients (20.5% vs. 39.6%,
p = 0.042). Furthermore, patients with hemoglobin values less than 10 g/dL had a significantly lower seroconversion
rate compared to those with higher hemoglobin values (20.0 vs. 38.6%, p = 0.049). By multivariate logistic regression
analysis, only age ≥65 years (OR = 0.336, 95% confidence interval (CI) 0.116-0.971, p = 0.044) and hemoglobin levels
<10 g/dL (OR = 0.315, 95% CI 0.106-0.932, p = 0.037) were independently associated with seroconversion after
vaccination.
Conclusions: Our data show that HD patients, especially who are elderly with low hemoglobin levels, are at
increased risk for lower seroconversion rate after influenza A/H1N1 vaccination. Further studies are needed to
improve the efficacy of vaccination in these high risk patients.
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End stage renal disease (ESRD) patients have complex
multifactorial causes of immune dysfunction and are at
high risk for influenza infection and its complications.
Following the outbreak of pandemic influenza A/H1N1
in 2009, the World Health Organization (WHO) and the
Korean Food and Drug Administration recommended
vaccination of pandemic influenza A/H1N1 vaccine for
all high risk individuals, including ESRD patients on
hemodialysis (HD) [1,2]. However, the current recom-
mendations for these high risk patients are based on
data from clinical trials performed on healthy subjects,
in which a single-dose vaccine provided a sufficient anti-
body seroconversion rate of 80 to 96% [2]. Compared
with the general population, HD patients have poor im-
mune responses to seasonal influenza vaccination [3].
Although mass vaccination for the pandemic influenza
A/H1N1 has been implemented in high risk groups, spe-
cific antibody responses after vaccination are lacking in
HD patients. Therefore, the purpose of the present study
is to investigate the antibody response rate to a single-
dose inactivated, pandemic H1N1 influenza vaccination
and establish possible clinical and biochemical para-
meters that may influence the induction of antibody
responses in HD patients.
Patients and methods
Study design
This multicenter, prospective observational cohort study
was conducted from December 2009 to March 2010.
Participating clinical sites included hemodialysis unit
from Gangnam Severance hospital, Bundang CHA
Medical Center, Yongin Severance Hospital, and three
private dialysis clinics. Clinically stable HD patients
were invited to participate in the study during their
routine hemodialysis treatments. Patients with fever
(temperature >38°C) or flu-like symptoms, age less
than 18 years old, known allergy to egg proteins, any
hospitalization within three months, liver diseases, ma-
lignancy, or treatment with immunosuppressive drugs
were excluded. A total of 114 HD patients on hemo-
dialysis thrice a week with synthetic membranes for
more than 3 months were enrolled. The causes of
ESRD were diabetic nephropathy (n = 62, 63.9%),
hypertension (n = 18, 18.9%), chronic glomeruloneph-
ritis (n = 6, 6.2%), polycystic kidney disease (n = 5, 5.2%),
and unknown origin (n = 6, 6.2%). The patients with
unknown origin had no clinical characteristics or lab
findings (ANA, complements, ANCA, anti-GBM anti-
body, etc.) of autoimmune diseases or immune-complex
glomerulonephritis. This study was approved by the
Institutional Review Board Committee of Gangnam
Severance Hospital (3-2009-0170). After informed con-
sent was obtained from the patients, baseline bloodsamples were taken before the midweek dialysis for
the determination of baseline hemagglutinin (HA) anti-
body titers, and the monovalent adjuvanted (MF59C1)
H1N1 inactivated influenza vaccine (Green-Flu-S
plusW3.75ug/0.25 ml, Green Cross Co. Ltd., Yongin,
Korea) was injected intramuscularly. Four weeks after
vaccination, blood samples were collected again for the
assessment of post-vaccination HA antibody titers.
Hemagglutination inhibition (HI) assay
The titers of neutralizing antibodies to pandemic influ-
enza virus were evaluated by HI assay according to the
standard WHO procedure with influenza A/Seoul/Y-01/
2009 virus [4].The sera were treated with receptor
destroying enzyme (RDE, Denka Seiken Co. Ltd., Tokyo,
Japan) by diluting 7 ul of serum with 21 ul RDE and
were incubated overnight at 37°C. The enzyme was inac-
tivated by 1 hr incubation at 56°C followed by addition
of 42 ul of PBS for a final dilution of 1:10. Virus suspen-
sions containing 4 HA units of virus were incubated for
1 h with serial 2-fold dilutions of antiserum. HI assays
were performed in V-bottom 96-well microtiter plates
with 1.0% chicken erythrocytes. HI titer was determined
as the reciprocal of the highest dilution that showed
complete inhibition of hemagglutination. Seroconversion
was defined as either a pre-vaccination HI titer < 1:10
and a post vaccination HI titer > 1:40 or a pre-
vaccination HI titer ≥ 1:10 and a minimum four-fold rise
in post-vaccination HI antibody titer.
Statistics
All statistical analyses were performed using SPSS
for Windows version 17.0 software (SPSS, Inc, an
IBM Company, Chicago, Illinois, USA). Values were
expressed mean ± standard deviation (SD) or percen-
tages. Differences between two groups according to
the immune response after vaccination were analyzed
by t-test in continuous variables or Chi-square test in
dichotomous variables. Non-parametric variables were
log-transformed before multivariate analysis. Binary lo-
gistic analysis was used for identifying independent
parameters associated with seroconversion after the
influenza A/H1N1vaccination. It was adjusted by sig-
nificant variables in the univariate analysis (p <0.15)
and known associated factors for HD patients [diabetes
mellitus (DM), albumin, ferritin levels and urea reduc-
tion rate]. Null hypotheses of no difference were
rejected if p-values were less than .05.
Results
There were 200 eligible HD patients, and 86 patients
declined to participate. The remaining 114 patients were
enrolled in the study and 17 out of 114HD patients
(14.9%) tested positive for influenza A/H1N1/2009 HA
Table 1 Baseline characteristics of the patients according to the seroconversion or not
Variables All patients (n = 97) Nonresponders (n = 67) Responders (n = 30) P-value
Age (years) 60.9 ± 12.6 63.1 ± 12.0 56.3 ± 12.6 0.012
Sex (Male,%) 54 (56.7) 35 (53.0) 19 (61.3) 0.445
Diabetes Mellitus (%) 62 (63.9) 44 (65.7) 18 (60.0) 0.591
Body mass index (Kg/m2) 22.7 ± 3.5 22.7 ± 3.6 22.8 ± 3.4 0.898
Duration of dialysis (mo)* 41.0 (25–41) 37.5 (22.8-66.3) 53.0 (31.0-82.0) 0.082
KT/V 1.44 ± 0.32 1.44 ± 0.33 1.41 ± 0.28 0.705
Urea reduction rate (%) 69.3 ± 7.9 70.0 ± 7.8 67.8 ± 8.2 0.193
Hepatitis B or C (%) 8 (8.2) 5 (7.5) 3 (10.0) 0.708
Medications (%)
Angiotensin converting enzyme inhibitor 18 (18.6) 11 (16.4) 7 (23.3%) 0.418
Angiotensin II receptor blocker 60 (61.9) 37 (55.2) 23 (76.7) 0.044
Calcium channel blocker 60 (61.9) 41 (61.2) 19 (63.3) 0.841
Beta blocker 49 (50.5) 30 (44.8) 19 (63.3) 0.194
Diuretics 53 (54.6) 38 (56.7) 15 (50.0) 0.539
Statins 40 (42.3) 28 (41.8) 12 (40.0) 0.868
Vitamin D analogue 5 (5.2) 4 (6.0) 1 (3.3) 0.587
White blood cell (/mm3) 6,450 ± 1,846 6,490 ± 1,977 6,368 ± 1,561 0.765
Lymphocyte count (/mm3) 1,376 ± 547 1,432 ± 568 1,225 ± 479 0.313
Hemoglobin (g/dL) 10.2 ± 1.1 10.0 ± 1.14 10.5 ± 0.85 0.032
MCV (fL) 93.7 ± 5.1 94.4 ± 5.3 91.4 ± 3.6 0.075
MCH (pg) 30.9 ± 1.7 31.1 ± 1.7 30.4 ± 1.3 0.153
MCHC (g/dL) 33.1 ± 1.1 33.0 ± 1.1 33.2 ± 1.1 0.546
Ferritin (ng/mL)* 159 (107–255) 159 (98–255) 155 (108–259) 0.367
C-reactive protein (mg/L)* 1.1 (0.5-4.7) 1.1 (0.5-4.3) 2.5 (0.45-6.1) 0.446
Glucose (mg/dL) 133 ± 48 134 ± 48 130 ± 48 0.74
Uric acid (mg/dL) 7.3 ± 1.3 7.2 ± 1.3 7.4 ± 1.4 0.241
Total Cholesterol (mg/dL) 149 ± 35 153 ± 40 149 ± 27 0.477
Albumin (g/dL) 4.0 ± 0.4 4.0 ± 0.4 4.0 ± 0.3 0.874
Alkaline phosphatase (IU/L) 91 ± 55 84 ± 50 101 ± 62 0.170
Total bilirubin (mg/dL) 0.31 ± 0.14 0.32 ± 0.15 0.29 ± 0.12 0.422
Triglyceride (mg/dL) 129 ± 94 133 ± 106 117 ± 60 0.351
HDL-cholesterol (mg/dL) 38 ± 13 37 ± 13 41 ± 14 0.332
Intact-parathyroid hormone (pg/mL) 160 ± 97 148 ± 96 188 ± 97 0.069
* was expressed by median (interquartile range).
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were no significant differences in demographic or bio-
chemical parameters between the patients who accepted
and refused to participate, and between pre-vaccination
HA antibody positive and negative patients (data not
shown). The remaining 97 baseline sero-negative
patients were thus included in the final analysis (male
54, mean age was 60.9 ± 12.6 years) for the study.
Among the 97 pre-vaccination antibody-negative
patients, only 30 (30.9%) had seroconversion (respon-
ders: ≥4-fold increase in titer) 4 weeks after influenza A/
H1N1 vaccination. The patients’ demographic, biochem-
ical parameters, dialysis adequacy and medications are
shown in Table 1. Demographic features such as gender,body weight, presence of DM, iron status reflected by
serum ferritin, and parathyroid hormone were not asso-
ciated with seroconversion rate.
HD patients who had seroconversion 4 weeks post-
vaccination were significantly younger (56.3 ± 12.6 vs.
63.1 ± 12.0 years, p = 0.012) and had higher hemoglobin
values (10.5 ± 0.85 vs. 10.0 ± 1.14 g/dL, p = 0.032) than
those who failed to show seroconversion (nonrespon-
ders). In particular, the elderly patients, those over
65 years of age, had significantly lower seroconversion
rates compared to younger HD patients (20.5 vs. 39.6%,
p = 0.042, Figure 1). In addition, patients with hemog-
lobin values greater than 10 g/dL had significantly higher
seroconversion rates compared to those with less than
Figure 1 The differences of seroconversion rate according to the age 65 years (a) and hemoglobin 10 g/dL (b).
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Patients were further divided into 4 groups by
hemoglobin level and age. (Group 1: Hb ≥ 10 g/dL and
Age < 65 years, Group 2: Hb ≥ 10 g/dL and Age ≥
65 years, Group 3: Hb < 10 g/dL and Age < 65 years,
Group 4: Hb < 10 g/dL and Age ≥ 65 years). Group 4
showed a significantly lower seroconversion rate com-
pared with Group 1 (10.0% vs 45.5%, p = 0.014). Logistic
regression analysis for seroconversion showed signifi-
cantly lower odds ratio for Group 4 (OR 0.133 (0.027-
0.669), p = 0.014) (Table 2).
Other variables specific for hemodialysis such as dia-
lysis dosage measured by Kt/V or urea reduction rate
and dialysis vintage were not associated with serocon-
version rate.
By logistic regression analysis adjusted by age,
hemoglobin, DM, angiotensin II receptor blocker usage,
serum albumin, ferritin, intact parathyroid hormone,
urea reduction rate, and log dialysis vintage, only age
older than 65 years (OR = 0.336, 95% confidence interval
(CI) 0.116-0.971, p = 0.044) and hemoglobin levels less
than 10 g/dL (OR = 0.315, 95% CI 0.106-0.932, p = 0.037)
were independently associated with seroconversion after
vaccination in HD patients (Table 3).
Except for mild to moderate local pain at the injection
site, no other serious side effects associated with the vac-
cination were observed in HD patients.
Discussion and conclusions
Our prospective observational cohort study investigated
the seroconversion rate to monovalent adjuvanted H1N1Table 2 Odds ratio for seroconversion by hemoglobin level 1
Patients group Odds ra
Group 1 (Hb≥ 10 g/dL and Age < 65 years) 1.0 (refer
Group 2 (Hb≥ 10 g/dL and Age≥ 65 years) 0.494
Group 3 (Hb < 10 g/dL and Age < 65 years) 0.514
Group 4 (Hb < 10 g/dL and Age ≥ 65 years) 0.133inactivated influenza vaccine in clinically stable HD
patients. The rate of seroconversion was 30.9% for all HD
patients. It is even lower than the previously reported
seroconversion rate for Korean diabetic patients by our
group and much lower than the one reported for normal
controls (68.1 ~ 84.4%) using the same vaccine [2,5]. The
reported seroconversion rate after influenza A/H1N1 vac-
cination is quite variable, from 33.3% to 64.2%, with con-
trasting results [6,7]. Compared with the healthy controls,
HD patients have a lower seroconversion rate and an in-
ability to maintain adequate antibody titers over time [8-
10]. The mechanism of uremia-associated hyporespon-
siveness to vaccination is still incompletely understood.
Over the past decade, a large number of studies have
shown that a variety of vaccines are less efficient in elderly
persons [11]. A clear association between older age and
poor immune response to HBV vaccine was shown in re-
cent meta-analysis in ESRD patients [12]. Similarly, other
studies showed that age significantly affected immune re-
sponse to influenza A (H1N1) vaccine in general popula-
tion [13,14]. Goodwin et al. reported that after adjusting
for vaccine and host factors, vaccine response in the eld-
erly was approximately 1/4 as rigorous for H1 and B anti-
gens and about 1/2 as rigorous for H3 antigens, compared
to the antibody response in younger adults [15]. The sero-
conversion rate of the elderly patients in the present study
was no more than 20.5%. In the multivariate logistic re-
gression analysis, age over 65 years was a significant risk
factor for hyporesponsiveness to influenza vaccine. The
mechanisms for age related change in the antibody re-
sponse are not fully understood, however, memory CD4+0 g/dL and age 65 years by logistic regression analysis





Table 3 Multiple logistic regression analysis of risk factors associated with seroconversion
Univariate Multivariate
Variables Odds ratio 95% CI Odds ratio 95% CI
Age (vs. < 65 year) 0.392 0.157-0.980 0.336 0.116-0.971
Hemoglobin (vs. ≥10 g/dL) 0.370 0.145-0.944 0.315 0.106-0.932
Diabetes mellitus (vs. non-DM) 0.784 0.323-1.905 0.912 0.319-2.604
ARB use (vs. non-ARB use) 2.664 1.006-7.052 1.785 0.597-5.333
Albumin (g/dL) 0.881 0.286-2.712 0.294 0.069-1.255
Ferritin (ng/mL) 1.002 0.999-1.004 1.002 0.999-1.005
Intact parathyroid hormone (pg/mL) 1.004 1.000-1.009 1.005 1.000-1.010
Urea reduction rate (%) 0.969 0.915-1.026 0.954 0.892-1.020
log dialysis duration 3.093 0.885-10.808 3.160 0.805-12.410
ARB, angiotensin II receptor blocker.
adjusted by age, hemoglobin, diabetes mellitus, angiotensin II receptor blocker, serum albumin, ferritin, intact parathyroid hormone, urea reduction rate, and log
dialysis duration..
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Th1 and Th2 cytokines are considered to be related with
the lower antibody response [16,17].
In contrast, there are some studies that did not ob-
serve “age factors” influencing antibody response to in-
fluenza vaccines [18,19]. The discrepancies in the
different studies’ results may be explained by differences
in types of vaccines used, use of adjuvants, host immune
factors, and previous vaccinations [3].
A recent large cohort trial (n = 355) employing one
dose schedule of pandemic H1N1 vaccine demonstrated
encouraging immunogenic profile in both adults and
elderly age-group [20]. While it is still controversial, two
doses of a pandemic vaccine to elicit an improved pro-
tective immune response has been recommended in
high risk immunocompromised patients [21-23]. Our
vaccination protocol consisted of one dose of intramus-
cular injection of monovalent adjuvanted (MF59C1)
H1N1 inactivated influenza vaccine. The vaccine used in
our trial fulfilled all international licensing criteria in
both the adult and elderly age-groups [24,25]. However,
it elicited lower immune response in elderly age-group
(over 65 years of age) compared to those of younger
adults (37.4 ~ 53.5% vs. 68.1 ~ 84.4%, respectively). This
immune response was significantly improved after a sec-
ond dose of vaccine administration (76 ~ 91%) [2].
Therefore, it may be prudent to measure baseline and
post-vaccination protective antibody titers against the
pandemic H1N1strain in high risk patients. Our results
provide alarming information on low immune response
to pandemic influenza vaccination in elderly HD patients
and further clinical trials administering second or
booster doses to improve seroconversion rates in high
risk patients may be warranted.
In contrast to other studies [7,10,26], hemoglobin
level less than 10 g/dL was a significant risk factor
for impaired seroconversion in the present study. Therelationship between anemia and poor antibody re-
sponsiveness after vaccination is an open question.
However, anemia is commonly associated with inflam-
mation and nutritional status of HD patients [27].
There are several studies that reported inflammation
and nutritional status as important risk factors of the
hypo-responsiveness after vaccination. Fulop et al.
observed that non-response group after influenza vac-
cination in the elderly patients had lower nutritional
parameters such as hemoglobin, total protein, iron,
vitamin E, and DHEA [28]. Recent research by Chang
et al. also suggested that hemoglobin level is a sig-
nificant predictor for seroresponse and seroconversion
in HD patients [19]. Our study did not have enough
power to assess the influence of inflammatory or nu-
tritional parameters on seroconversion. However, con-
sidering these relationship, we suggest that anemia
may be a risk factor for hypo-responsiveness after vac-
cination. Furthermore, when the patients were divided
into 4 groups by hemoglobin level and age, Group 4
(Hb < 10 g/dL and Age ≥ 65 years) had a significant
lower seroconversion rate and odds ratio for serocon-
version compared with Group 1 (Hb ≥ 10 g/dL and
Age < 65 years). Group 2 and 3 did not differ from the
reference Group 1. These results show that combined
age and anemia, defined as hemoglobin level less than
10 g/dL, are significant additional risk factors for sero-
conversion after influenza vaccination.
Other factors influencing seroconversion have been
investigated in several trials but no definite common factor
has been identified. Some investigators reported that very
high ferritin levels may suppress antibody production fol-
lowing influenza vaccination in HD patients [29], but our
results and other investigators have not found any definite
association between iron status and seroconversion rate.
Recently, a weaker immune response to non-adjuvanted
2009 influenza A (H1N1) vaccine (PanenzaW; Sanofi
Moon et al. BMC Nephrology 2012, 13:165 Page 6 of 7
http://www.biomedcentral.com/1471-2369/13/165Pasteur, France) was reported in HD patients dialyzed
twice a week whereas other HD patients undergoing dialy-
sis 3 times a week showed comparable immune response
to healthy controls [26].However, their results should be
interpreted with caution as half of the study participants
were underdialyzed and non-adjuvanted vaccine was used
for vaccination. All of our patients underwent hemodialysis
treatment 3 times a week and the achieved dialysis dose
and time on dialysis were comparable between responders
and non-responders. Moreover, most of other studies
evaluating the efficacy of influenza A H1N1/2009 vaccine
using adjuvanted vaccine have shown that dialysis dose or
degree of uremia does not influence seroconversion [6,7].
Compared to non-diabetic patients, diabetic patients
had an impaired immune response to influenza vaccin-
ation [30]. In our previous study on diabetic patients,
only 48.6% of patients achieved seroconversion after a
single-dose adjuvanted, inactivated, pandemic H1N1 in-
fluenza vaccination [5]. The hemodialysis patients in the
present study, however, did not show significant effect of
DM on the seroconversion rate. Furthermore, subgroup
analysis according to age and gender showed no signifi-
cant effect of DM on seroconversion (data not shown).
This observed discrepancy may be explained by several
causes. First, age of our seroresponders in diabetic
patients was younger compared to that of nonresponders
(57.5 ± 11.1 vs. 65.1 ± 11.5 years, p = 0.021). Advanced
age negatively affects the seroconvesion rate regardless
of the patient’s status [12,31]. Second, uremic milieu per
se is commonly believed to be the cause of poor sero-
conversion in ESRD patients. Our results are in accord
with recent study from Taiwan, which reported no
significant differences between DM and non-DM HD
patients [19]. Another possible explanation might be
the seroconversion rate of our patients was very low
(30.8%) and could have undermined the effect of
DM. Non-diabetic HD patients had a similarly poor
seroconversion rate as their diabetic counterparts, sug-
gesting that state of uremia per se is associated with
substantial immunodeficiency.
There are several limitations in this study. First,
healthy controls were not included in the study. There-
fore, we could not compare the seroconversion rate be-
tween HD patients and healthy controls. However, the
seroconversion rate for healthy Korean individuals using
the same adjuvanted vaccine is 68.1%, clearly greater
than our HD patients. Second, the number of patients is
small and previous vaccination history was not surveyed.
Nevertheless, the efficacy of influenza vaccination in the
present study is relatively consistent with other studies
[6]. Third, long-term immunogenicity of influenza vac-
cination was not investigated in our study. Short term
immune responses to influenza vaccination have been
well studied but long-term immune response in HDpatients are lacking. Long-term immunogenicity results
would be more helpful in directing immunization sched-
ule for these high risk patients.
In conclusion, we found that administration of a single
dose adjuvanted monovalent H1N1 inactivated influenza
vaccine induced relatively a poor immune response in
HD patients. In particular the elderly HD patients with
lower hemoglobin levels are at much increased risk. Fur-
ther trials with larger number of patients and different
vaccination schedules employing different vaccine doses
or boosters are warranted.
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